Related Experiment Video
Updated: Feb 16, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi1, Terra L Lasho1, Christy M Finke1
1Division of Hematology, Department of Internal Medicine.
Abstract:
A myeloid neoplasm-relevant 27-gene panel was used for next-generation sequencing of bone marrow or whole blood DNA in 182 patients with primary myelofibrosis (PMF). DNA sequence variants/mutations other than JAK2/CALR/MPL were detected in 147 patients (81%), with the most frequent being ASXL1 (36%), TET2 (18%), SRSF2 (18%), and U2AF1 (16%); furthermore, 35%, 26%, 10%, and 9% of the patients harbored 1, 2, 3, or 4 or more such variants/mutations, respectively. Adverse variants/mutations were identified by age-adjusted multivariable analysis of impact on overall survival or leukemia-free survival and included ASXL1, SRSF2, CBL, KIT, RUNX1, SH2B3, and CEBPA; their combined prevalence was 56%. Adverse variants/mutations were associated with inferior overall survival (median, 3.6 vs 8.5 years; P < .001) and leukemia-free survival (7-year risk, 25% vs 4%; P < .001), and the effect on survival was independent of both the Dynamic International Prognostic Scoring System Plus and JAK2/CALR/MPL mutational status, with respective hazard ratios of 2.0 (95% confidence interval [CI], 1.3-3.1) and 2.9 (95% CI, 1.9-4.4). Additional prognostic information was obtained by considering the number of adverse variants/mutations; median survivals in patients with zero (n = 80), 1 or 2 (n = 93), or 3 or more (n = 9) adverse variants/mutations were 8.5, 4, and 0.7 years, respectively (P < .001). Additional data were obtained on pattern of mutation co-segregation and phenotypic correlation, including significant associations between U2AF1 and JAK2 mutations (P = .04) and U2AF1 mutations and anemia (P = .003) and thrombocytopenia (P = .006). We conclude that DNA variants/mutations other than JAK2/CALR/MPL are prevalent in PMF and are qualitatively and quantitatively relevant in predicting overall and leukemia-free survival.
Insights
Genetic mutations beyond JAK2/CALR/MPL are common in primary myelofibrosis (PMF) and significantly impact patient survival. Identifying these adverse mutations improves prognostic accuracy for overall and leukemia-free survival in PMF patients.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis.
- The prognostic significance of genetic mutations, particularly JAK2, CALR, and MPL, is well-established in PMF.
- However, the role of other genetic variants in PMF prognosis requires further elucidation.
Purpose of the Study:
- To investigate the prevalence and prognostic impact of DNA sequence variants/mutations other than JAK2/CALR/MPL in patients with PMF.
- To identify specific adverse mutations and assess their contribution to overall survival (OS) and leukemia-free survival (LFS).
- To evaluate the combined prognostic value of these additional mutations, independent of existing scoring systems.
Main Methods:
- Next-generation sequencing (NGS) of a 27-gene panel was performed on bone marrow or whole blood DNA from 182 PMF patients.
- Age-adjusted multivariable analysis was used to identify adverse variants/mutations impacting OS and LFS.
- Statistical analyses, including survival curves and hazard ratios, were employed to assess prognostic significance.
Main Results:
- 81% of patients harbored variants/mutations other than JAK2/CALR/MPL, with ASXL1, TET2, SRSF2, and U2AF1 being most frequent.
- Adverse variants/mutations (ASXL1, SRSF2, CBL, KIT, RUNX1, SH2B3, CEBPA) were present in 56% of patients and associated with inferior OS (3.6 vs 8.5 years) and LFS (7-year risk, 25% vs 4%).
- The prognostic impact of these adverse mutations was independent of the Dynamic International Prognostic Scoring System Plus and JAK2/CALR/MPL status, with a significant increase in risk for OS and LFS.
Conclusions:
- DNA variants/mutations beyond JAK2/CALR/MPL are prevalent in PMF and carry significant prognostic information.
- The number and specific types of adverse mutations identified provide additional predictive value for overall and leukemia-free survival.
- These findings underscore the importance of comprehensive genetic profiling for improved risk stratification and management of PMF patients.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Sequences
Sanger Sequencing
Arithmetic Sequences
Geometric Sequences

